Repeated administration of Delta(9)-tetrahydrocannabinol produces a differential time related responsiveness on proenkephalin, proopiomelanocortin and corticotropin releasing factor gene expression in the hypothalamus and pituitary gland of the rat
J. Corchero et al., Repeated administration of Delta(9)-tetrahydrocannabinol produces a differential time related responsiveness on proenkephalin, proopiomelanocortin and corticotropin releasing factor gene expression in the hypothalamus and pituitary gland of the rat, NEUROPHARM, 38(3), 1999, pp. 433-439
The purpose of the present study was to explore the time related effects of
repeated administration of Delta(9)-tetrahydrocannabinol on opioid and cor
ticotropin releasing factor gene expression in the hypothalamus and pituita
ry gland of the rat. By using in situ hybridization histochemistry, the eff
ects of Delta(9)-tetrahydrocannabinol (THC, 5 mg/kg per day; i.p.) were exa
mined after 1, 3, 7 and 14 days of repeated administration on; (1) proenkep
halin gene expression in the paraventricular (PVN) and ventromedial nuclei
(VMN) of the hypothalamus, (2) proopiomelanocortin gene expression in the a
rcuate nucleus (ARC) of the hypothalamus and anterior (AL) and intermediate
lobe (IL) of the pituitary gland, and (3) corticotropin releasing factor g
ene expression in the PVN. The results revealed that, in most of the hypoth
alamic and pituitary regions examined, repeated cannabinoid administration
upregulates opioid and corticotropin releasing factor gene expression. Howe
ver, the onset, the degree of magnitude of gene expression reached and the
time related effects produced by repeated administration with Delta(9)-tetr
ahydrocannabinol are dependent upon the brain and pituitary regions examine
d. Taken together, the results of the present study suggest that cannabinoi
ds produce a time related differential responsiveness in opioid and cortico
tropin releasing factor gene expression, in areas of the hypothalamus and p
ituitary that may be related, at least in part, to a molecular integrative
response to behavioral, endocrine and neurochemical alterations that occur
in cannabinoid drug abuse. (C) 1999 Elsevier Science Ltd. All rights reserv
ed.